Dr Dilip Surana, CMD of Micro Labs Limited, hails tariff shield as a landmark step that strengthens India’s $9 billion pharma exports to the US, meeting nearly half of America’s generic drug demand while easing patient cost burdens. New Delhi/Washington – The India–US bilateral trade
Recent Posts
- Pharma Leaders 2026 : Reimagining Healthcare – Powering Trust, Innovation & Global Impact
- The Earthquake in Tehran: Khamenei’s Death and the Shattered Chessboard
- US–Iran Standoff: A Global Flashpoint – Power Politics Overrule Diplomacy
- United States Supreme Court Schools Donald Trump: A Historic Rebuke of Executive Overreach
- Shashi Tharoor Tears Into Union Budget 2026–27: “Promises Without Commitment”










